Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
Muhammad Wasif Saif GI Oncology Program, Tufts University School of Medicine, Boston, MA, USA Abstract: Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the angiogenesis pathway. Despite benefits of bevacizumab in cancer the...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-06-01
|
| Series: | Cancer Management and Research |
| Online Access: | http://www.dovepress.com/anti-vegf-agents-in-metastatic-colorectal-cancer-mcrc-are-they-all-ali-a13312 |